Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LTP001 in pulmonary arterial hypertension
NL-OMON51446Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing LTP001 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Pulmonary vascular resistance at Week 25. Started Jan 2023; status: completed.
02
Drugs
LTP001
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NL-OMON51446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51446.